The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > COMMENTARY
COMMENTARY
- COMMENTARY/Combination Drugs Becoming a "Boom"
June 1, 2009
- COMMENTARY/Clearer Criteria Needed for Patent Period Restoration
May 4, 2009
- COMMENTARY/Why Does the Use of Generics Not Increase?
April 27, 2009
- EMTs Allowed to Administer Epipen
April 27, 2009
- COMMENTARY/Medway Data Falsification to Make Blood Product Self-Sufficiency Difficult
April 20, 2009
- The First Round Results of GE Amlodipine (2)- Making No Surprise Moves Leads to Success -
April 6, 2009
- COMMENTARY/Worst Scenario Coming True due to Heated Competition among Wholesalers
March 23, 2009
- Unexpected Demand for ActHIB Causes Shortage of Supply
March 16, 2009
- COMMENTARY/Aggressive Overseas Investments Affect Business of Top-4 Pharmas
February 23, 2009
- COMMENTARY/National Consensus Needed to Balance Soaring Costs of New Drugs against Their Benefits
February 16, 2009
- Majority of People Have Misconceptions about Antibacterials: Pfizer Survey
February 9, 2009
- Patent Expiration of Blockbusters and New Breakthrough Candidates from Japanese Pharmaceutical Companies
February 9, 2009
- Paltac/Alfresa Merger Plan Canceled, but Distribution Reform Remains to Be Done
February 2, 2009
- COMMENTARY/Industry Should Guarantee Development of Innovative Drugs and Use of More Generics
January 19, 2009
- COMMENTARY/Aiming at Further Growth beyond Global Recession
January 12, 2009
- COMMENTARY/Rule to Restrict Participation in CDFS Committee Deliberations Needs Continued Validation
January 5, 2009
- COMMENTARY/Will Economic Incentives for Med. Institutions Be Effective to Promote Use of Generics?
December 22, 2008
- Commentary/Issue of Online Sales of OTC Drugs at Standstill
December 15, 2008
- COMMENTARY/Toyota, NEC Start Direct Inspection, Payment of Medical Bills
December 8, 2008
- COMMENTARY/Will VITAL KSK Become Core of Alliance of Regional Wholesalers?
December 8, 2008
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…